Revenue growth is already strong but GSS says "accelerated revenue growth is anticipated following the upcoming regulatory registrations of a number of the EasyScreen Detection Kits, including the STI and Respiratory Pathogen Detection Kits."
With $2.6m R&D tax credit due in the current quarter, GSS's balance sheet is strong, and subject to revenue growth it may achieve cash breakeven in the next 12-24 months without the need for another capital raising.
Hopefully this may be the case (although one can possibly be too optimistic in this regard). But, overall the results are strong and pleasing.
The other positive aspect is that, although small, GSS is a genuinely global business with products that are attractive in the global market place and with repeat business. This is nice to see.
- Forums
- ASX - By Stock
- GSS
- Ann: Appendix 4C - quarterly
GSS
genetic signatures limited
Add to My Watchlist
3.95%
!
36.5¢

Ann: Appendix 4C - quarterly, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
36.5¢ |
Change
-0.015(3.95%) |
Mkt cap ! $82.90M |
Open | High | Low | Value | Volume |
37.0¢ | 37.0¢ | 36.5¢ | $7.667K | 20.72K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 16957 | 36.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 4419 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 16957 | 0.365 |
2 | 3407 | 0.360 |
1 | 40000 | 0.355 |
4 | 130509 | 0.350 |
1 | 1683 | 0.300 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 4419 | 1 |
0.390 | 20000 | 1 |
0.400 | 111918 | 2 |
0.420 | 40000 | 2 |
0.455 | 5000 | 1 |
Last trade - 13.27pm 10/07/2025 (20 minute delay) ? |
Featured News
GSS (ASX) Chart |